Journal ArticleOPEN ACCESS

Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA

  • Reungwetwattana T
  • Gray J
  • Markovets A
  • et al.
Annals of Oncology (2019) 30 ix199
DOI: 10.1093/annonc/mdz446.016
N/ACitations
Citations of this article
21Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

… FLAURA. Methods. Treatment-naïve patients (pts) with EGFRm (ex19del/L858R) locally advanced/metastatic NSCLC (n = 556) were randomised 1:1 (osimertinib 80 mg qd: comparator [gefitinib 250 mg qd/erlotinib 150 mg qd]) …

Cite

CITATION STYLE

APA

Reungwetwattana, T., Gray, J., Markovets, A., Nogami, N., Lee, J. S., Cho, B. C., … Ramalingam, S. (2019). Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA. Annals of Oncology, 30, ix199. https://doi.org/10.1093/annonc/mdz446.016

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free